16955246_mlNews

Click on an item below to view/download the press release (PDF)

2018

ImmunogenX Completes CypCel Trial for Celiac Disease (September 2018)

AJCN Publication Garnering Tremendous Interest (March 2018)

2017

NIH Awards Grant to ImmunogenX to Study Latiglutenase (October 2017)

Dr. Markku Mäki Joins the Scientific Advisory Board  (October 2017)

New Latiglutenase Analyses Published in Digestive Disease & Science (August 2017)

ImmunogenX to Make Highlighted Presentations at DDW 2017 (January 2017)

Dr. Ciaran P. Kelly Joins the Scientific Advisory Board (January 2017)

2016

ImmunogenX Invited to Present at the Medical Device & Investor Forum (November 2016)

ImmunogenX Invited to Present at the Pharmaceutical Strategy Conference (October 2016)

ImmunogenX Donates Patient Reported Outcome Instruments to
the Foundation for Celiac Disease Outcome Measures (May 2016)

ImmunogenX Acquires the Assets of Alvine Pharmaceuticals (March 2016)

2015

ImmunogenX has closed a Class B overscribed investment round (October 2015)

ImmunogenX expands its Scientific Advisory Board (September 2015)

Detection of gluten in probiotics (May 2015)

2014

ImmunogenX signs agreement with Flamentera to acquire rights to CypCel diagnostic for celiac disease management (May 2014)

ImmunogenX makes key additions to its Scientific Advisory Board (May 2014)

ImmunogenX has completed a Series A investment round  (April 2014)


2013

ImmunogenX formed to develop advanced diagnostics and screening tools for celiac disease (July 2013)